Methazolamide

Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage[1][2][3].

Product Specifications

CAS Number

[554-57-4]

Product Name Alternative

L584601

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Carbonic Anhydrase; Caspase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/methazolamide.html

Purity

99.43

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CC(/N=C1SC(S(=O)(N)=O)=NN/1C)=O

Molecular Formula

C5H8N4O3S2

Molecular Weight

236.27

Precautions

H302, H315, H319, H335

References & Citations

[1]Yang F, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016;16 (1) :83-87.|[2]Abbate F, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J Enzyme Inhib Med Chem. 2003;18 (4) :303-308.|[3]Li M, et al. Methazolamide improves neurological behavior by inhibition of neuron apoptosis in subarachnoid hemorrhage mice. Sci Rep. 2016 Oct 12;6:35055.